Drugs / GSK249320A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00622609 | Aug 2007 → Apr 2009 | stroke disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK249320A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00622609 ↗ |
| Known as | GSK249320 | “GSK249320, a monoclonal antibody directed against myelin-associated glycoprotein (MAG), is being developed for the enhancement of recovery of function poststroke.” PMID 23267856 ↗ Nov 2012 |
| Action | Inhibit | “GSK249320 acts as a MAG antagonist” NCT00622609 ↗ |
| Modality | Monoclonal antibody | “GSK249320 is a monoclonal antibody directed against myelin-associated glycoprotein (MAG)” NCT00622609 ↗ |
| Route | Intravenous | “administered as a slow intravenous infusion over 1 hour on Day 1.” NCT00622609 ↗ |
| Target | MAG | “GSK249320 is a monoclonal antibody directed against myelin-associated glycoprotein (MAG)” NCT00622609 ↗ |